Abstract: The presently disclosed and claimed inventive concept(s) provides new estrogenic compounds of the general formula and pharmaceutical compositions containing them. The compounds of the presently disclosed and claimed inventive concept(s) are useful, for example, in hormone replacement therapies (HRT/ERT), and as contraceptives, and estrogenic hormone therapies. Also provided is a process for synthesizing the compounds of the presently disclosed and claimed inventive concept(s).

Abstract: The present invention refers to tricyclic diterpenes and their derivatives of the formulae (I) and (II), wherein R1 is hydrogen or C1-6-alkyl; R2 is hydroxy, C3-5-acyloxy, hydroxymethyl, 1,3-dihydroxypropyl or C1-6-alkyl; R3 and R4 independently from each other are hydrogen, hydroxy, hydroxymethyl, C1-5-acyloxy or C1-6-alkoxy; R5 is C1-6-alkyl, hydroxymethyl carboxy or methoxycarbonyl; R9 is hydrogen, hydroxymethyl, methoxy, oxo or C1-5-acyloxy; R10 is hydrogen, or R5 and R9 taken together are —CH2—O— or —O—CH2—; or R5 and R10 taken together are —CO—O—, —O—CO—, —CH2—O— or —O—CH2—; R6 is hydrogen, or R5 and R6 together form a bond; R7 and R8 independently from each other are C1-6-alkyl, carboxy, x-hydroxy-Cx-alkyl (with x being an integer from 1 to 6), or C1-6-alkoxycarbonyl with the proviso that at least one of R7 and R8 is C1-6-alkyl; R11 and R12 are both hydrogen or R11 and R12 together are oxo, with the further proviso for formula (I) that if R2 is hydroxy R1 is C1-6-alkyl, for use as medicaments for the t

Abstract: A composition-of-matter comprising a substance usable in producing packaging material and at least one compound selected from the group consisting of ar-turmerone, a sesquiterpene alcohol and a turmeric oleoresin solid residue.

Abstract: The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases.

Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

Abstract: A method and composition for protecting and/or treating neuroinjury are disclosed. In one aspect, the present application discloses a method for protecting and/or treating a subject from organophosphate-induced neuronal injury. The method comprises administering to a subject an effective amount of 4R cembranoid, 4S cembranoid or a cembranoid analogue. In another aspect, the application discloses neuroprotective pharmaceutical compositions for protecting and/or treating a subject from organophosphate-induced neuronal injury. A kit for protecting and treating a subject from organophosphate-induced neurodamage is also disclosed.

Abstract: Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular Demodex infestations and related conditions using such compositions.

Abstract: The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.

Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed, in particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.

Abstract: Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addition/cyclization sequence followed by functional group manipulation to develop functionalized compounds that can target neuraminidase, which makes them ideal candidates for treating influenza. Pharmaceutical compositions comprising the therapeutic compounds and biologically-acceptable materials are also described. Methods of inhibiting neuraminidase in subjects that are suspected of containing neuraminidase are also described. The use of metabolites of the disclosed compounds can also be used in diagnostic assays for therapeutic dosing of the disclosed compounds.

Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.

Abstract: The present invention provides convergent processes for preparing (?)-beta-elemene, (?)-beta-elemenal, (?)-beta-elemenol, and (?)-beta-elemene fluoride and analogues thereof. Also provided are intermediates useful for preparing (?)-beta-elemene. The present invention further provides novel compositions based on analogues of (?)-beta-elemene, (?)-beta-elemenal, (?)-beta-elemenol, (?)-beta-elemene fluoride and methods for the treatment of cancer, such as brain tumor, lung cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric intestional cancer, and stomach cancer.

Abstract: Methods are described for treating or preventing a respiratory infection by administering an effective amount of a TRP channel agonist.

Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.

Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.

Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a tertiary system, in which menthol may form part of the eutectic mixture or in the eutectic mixture comprises an antidandruff agent such as ketoconazole.

Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.

Abstract: Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.

Abstract: The present invention provides an antibacterial oral rinse formulation having enhanced antibacterial activity against oral bacteria associated with infectious and inflammatory processes for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting the transient bacteremia associated with oral hygiene activities by the individual. Also provided is a method for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting transient bacteremia associated with oral hygiene activities by the individual, comprising rinsing with the antibacterial oral rinse formulation for a period of time immediately prior to engaging in oral hygiene activities.

Abstract: Topically absorbable compositions with bioactive or bioavailable cannabis-derived cannabinoids known to be effective for CB1 or CB2 modulation, and a plurality of indications for patients in need, and methods for producing composition, without detectable or biologically active levels of THC. Method uses a heat cycle process to combine cannabinoids with flax seed oil and at least one triglyceride, to produce an extract. The extract can include non-psychoactive agents, namely, CBD and accordingly does not deleteriously impact federal legal schemes or bone fide drug-testing regimes.

Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.

Abstract: The invention concerns the cosmetic or dermatological use of at least one compound of formula (I), wherein: R1, R2, R3, R4, R5 and G are such as defined in the description as whitening and/or depigmenting agents for the skin and/or hairs and/or the hair. The invention also concerns a cosmetic method for whitening and/or lightening the skin and/or hairs and/or the hair comprising applying a composition of the invention.

Abstract: Provided in the present invention are a composition for ameliorating or treating a diabetic condition and methods of making and using the same.

Abstract: The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.

Abstract: The invention relates to a medicinal product which is free from sympathomimetics, has an advantageous effect on the nasal mucosa in case of common colds, hay fever, dry nose and sympathomimetic dependencies, and is provided in the form of a nasal spray, a nasal douche or nasal drops.

Abstract: A composition provides an isotonic nasal irrigation solution with pH less than about 7.0. The composition may be formed of a salt and a pH buffer and may include an additive. The composition may be mixed with water to form the solution. The composition may aid in the treatment of various nasal or sinus disorders such as, for example, dryness, rhinitis, and sinusitis. The isotonic irrigation solution may also aid in the removal of contaminants from the sinus and nasal cavities such as blood, mucus, dirt, pollen, allergens, viruses, and bacterial. The composition may be liquid or dry.

Abstract: Some embodiments comprise tea tree oil derivatives, and compositions and uses of same, which have decreased cytotoxic and irritating characteristics.

Abstract: An object of the present invention is to provide a skin temperature elevating agent that can further effectively raise a skin temperature. Another object is to provide a cosmetic composition, a food and a sundry article having a skin temperature elevating effect. A skin temperature elevating agent of the present invention is selected from one or more selected from a group consisting of: an extract of Japanese peppermint; an extract of clary sage; dihydro-?-ionol; and geraniol, and thus it can raise a skin temperature of a cheek. The skin temperature elevating agent according to the present invention is also selected from one or more selected from a group consisting of: an extract of Japanese peppermint; an extract of juniper berry; and 4-methoxystyrene, and thus it can raise a skin temperature of a hand fingertip. Hence, the skin temperature elevating agent according to the present invention can further effectively raise a skin temperature.

Abstract: The present invention relates to five-layered pigments based on multicoated platelet-shaped substrates which comprise a layer sequence comprising (A) a layer of SnO2 having a layer thickness of 0.1-50 nm, (B) a high-refractive-index coating consisting of TiO2 in the rutile modification having a layer thickness of 10-800 nm, (C) a colorless coating having a refractive index n?1.8 having a layer thickness of 20-800 nm, (D) a high-refractive-index coating consisting of SnO2 having a layer thickness of 0.1-50 nm, (E) a layer of TiO2 in the rutile modification having a layer thickness of 10-800 nm, and optionally (F) an outer protective layer, and to the use thereof in paints, coatings, powder coatings, printing inks, security printing inks, plastics, ceramic materials, glasses, as dopants for the laser marking of papers and plastics, in cosmetic formulations and for the preparation of pigment preparations and dry preparations.

Abstract: To provide an antibacterial agent effective against gram-positive bacteria, particularly an antibacterial agent that is safe even when added to foods and the like, and a disinfecting method. An antibacterial agent comprising as an active ingredient either one or both of compounds represented by the following formula (1) and (2) contained in a labiatae plant extract: This antibacterial agent has antibacterial activity against gram-positive bacteria belonging to the genus Staphylococcus, the genus Lactobacillus, the genus Listeria, the genus Alicyclobacillus or the genus Bacillus.

Abstract: An object of the present invention is to provide a novel technology for preventing crystal precipitation of p-menthane-3,8-diol, and stable products utilizing this technology. Provided is a p-menthane-3,8-diol isomer mixture, wherein the mass ratio of cis isomers:trans isomers in terms of the relative configuration at Positions 3 and 4 is 55:45 to 45:55. Also provided are stable products and the like containing the p-menthane-3,8-diol isomer mixture.

Abstract: This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating migraine in a subject.

Abstract: Provided is a composition including, as an active ingredient, at least one selected from the group consisting of amines, amides and polyols. The cosmetic composition has an effect of preventing aging and may be applied in various industrial fields, including cosmetics.

Abstract: The present invention relates to the use of 3-methyl-6-(1-methylethenyl)cyclohex-3-ene-1,2-diol, its isomers and derivatives, as a compound for Parkinson disease treatment, that can be used in medicine. The compound is highly active, low toxic and can be synthesized from available natural compound ?-pinene.

Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.

Abstract: Insecticidal compositions have at least one active agent and at least one insecticide. The active agent can include perilla oil, a component found in perilla oil, or a perillaldehyde or carvone analog. The insecticide can include a pyrethrum, pyrethrin, pyrethroid, neonicotinoid, chlofenapyr, ethiprole, sulfoxoflor, carbamate, organophosphate, or organochlorine. Methods for controlling insects include contacting an insect with an effective amount of a composition described in this specification. Modified plants that produce an active agent can be contacted with an insecticide.

Abstract: The present invention provides a substance which promotes the transdermal absorption of a pharmacologically active component while little irritating the skin. The present invention relates to a transdermal absorption promoter which comprises, as the active component, at least one member selected from among isopulegol, 2-(menthoxy)ethanol and 2-methyl-3-(menthoxy)propane-1,2-diol; and an external skin formulation which comprises a pharmacologically active component such as a psychotropic component, an anti-inflammatory component, an analgesic component, an antipyretic component, a whitening component or a hair growth-promoting component, together with the aforesaid transdermal absorption promoter.

Abstract: A liquid evaporative cooling composition has been discovered which is peculiarly effective in providing relief from heat-related discomfort. The composition utilizes a concentrate, dissolved in water, which preferably consists essentially of (a) about forty-three percent by weight of an alcohol; (b) about twelve percent by weight of a surfactant; (c) about four percent by weight of an aromatic oil; (d) about one percent by weight of a cooling agent; and (e) about forty percent by weight of water. Various ranges of concentrations for the composition components have been discovered, the concentration ranges featuring various advantages and disadvantages, and these ranges are disclosed herein. The composition can be applied to the surface to be cooled (typically, a user's skin) in a number of ways and has even been found to relieve heat-related discomfort in animals.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: A composition beverage and method for relieving a symptom of a sore throat of a user. The composition comprises an aqueous base and an effective amount of a throat soreness relieving agent. The relieving agent may comprise between 0.001% w/v and 0.02% w/v of menthol. The beverage comprises a water base and including between 0.001% w/v and 0.02% w/v of a throat soreness relieving agent. The method comprises the administration of a safe and effective amount of a composition comprising an aqueous base and an effective amount of a throat soreness relieving agent.

Abstract: An excellent potential-dependent cation channel inhibitor or an excellent masking agent is provided.

Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: An emulsion comprising L-Menthol, a fat or oil and a surfactant wherein oil particles have an average diameter of 100 nm or less inhibits a content reduction attributed to, for example, evaporation of L-menthol, enhances a light transmission through liquid and is stable despite long-term storage. Thus, the emulsion can be appropriately used in the temporary inhibition of contraction of gastrointestinal tract for, for example, observation of gastrointestinal tract by an endoscope. This emulsion can be obtained by heating an oil-in-water type emulsion comprising L-menthol, a fat or oil and a surfactant at 60° C. or higher.

Abstract: Disclosed is a composition comprising MZ for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject.

Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of IAPP or amylin fibril diseases, and the manufacture of medicaments for such treatment.

Abstract: Provided herein are compositions of sandalwood oil and methods of making and using such compositions.

Abstract: The invention provides compounds of Formula (I): R1?R2??(I) wherein R1 and R2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.

Abstract: The present invention relates to a method of preparing for an oil suspension of carotenoid with low viscosity and high fluidity and use thereof. The method comprises the following steps: mixing carotenoid crystals with tetrahydrofuran, heating the mixture to reflux temperature 50˜70°C. under stirring to dissolve the crystal, filtering and condensing to obtain the concentrate; mixing the concentrate with ketone solvent, heating the mixture to reflux temperature 60-80? to dissolve the concentrate, filtering, condensing, adding absolute alcohol, crystallizing under stirring at room temperature, filtering and drying in vacuum to obtain carotenoid crystals; mixing carotenoids crystals after granded with plant oil or grinding carotenoid crystals with plant oils and then adding plant oil, to obtain the oil suspension of carotenoid with low viscosity and high fluidity. While the content of carotenoid is 10.0˜45.0 wt.